New LaunchJun 16, 2026, 08:32 AM
Optimi Health Launches 1mg & 2mg Microdose Psilocybin Products
AI Summary
Optimi Health Corp. announced the launch of two new standardized microdose psilocybin finished drug products, formulated at 1mg and 2mg dosages. These naturally derived capsules provide consistent, validated doses for qualified clinical research organizations. This expands Optimi's psilocybin range, which already includes a 5mg formulation commercially prescribed in Australia for treatment-resistant depression. All products are produced in-house at Optimi's wholly owned GMP facility in Princeton, British Columbia, Canada.
Key Highlights
- Optimi Health launched 1mg and 2mg standardized microdose psilocybin finished drug products.
- These naturally derived products provide validated, consistent doses for clinical research.
- The new microdose formats are available to qualified, authorized clinical research organizations.
- This expands Optimi's psilocybin range, which includes a 5mg formulation.
- The 5mg capsule is currently prescribed for treatment-resistant depression in Australia.
- All products are produced start-to-finish in-house at Optimi's GMP facility in Canada.
Price Impact
More from OPTH